axogeninc.com - AXGN Company Value to Revenue Ratio

Public company logo of Axogen (AXGN)

AxoGen, Inc. (AXGN) leverages its patents and clinical foundation to create an insurmountable barrier for competitors in neurosurgery. Stable margins are driven by the mass integration of implants into surgical protocols, while flawless sterile logistics guarantee deliveries. The company's enterprise value-to-revenue trend visualizes the asset's revaluation dynamics, with the current metric standing at 11505.11, allowing for an objective business assessment regardless of debt load.

AXGN AxoGen, Inc.: EV/Sales Multiple in the range 11/23/2025 - 11/19/2026

AXGN (Axogen Corp): analytical breakdowns and indicator data

Fundamental valuation:AxoGen, Inc. AXGN
Mass-produced product of AxoGen Inc

This indicator compares the total enterprise value to sales volume, eliminating the impact of leverage on the valuation. It allows for a determination of whether an asset's market price is fair relative to its ability to generate revenue. By analyzing the EV/Sales ratio, an investor identifies risks of overvaluation or undervaluation of the company. For AxoGen, Inc. (AXGN), this is critical, as a high dependence on external tissue suppliers affects margins. The stability of this metric confirms the resilience of the business model when outsourcing key processes.

Competitor analysis for AxoGen, Inc.

BSX (Boston Scientific) - Company Value to Revenue Ratio|EW: EV/Sales Multiple|RMD - Total Company Value-to-Revenue Ratio|PODD (Insulet Inc.) - EV/Sales Multiple|Company Value to Revenue Zimmer Biomet Corp (ZBH)|EV/Sales Multiple COO|Company Value to Revenue Align Technology, Inc. ALGN|EV/Sales Multiple GMED (globusmedical.com)|EV/Sales Multiple TransMedics Group, Inc. TMDX|ATEC - Enterprise Value-to-Revenue Ratio|AORT: Enterprise Value-to-Revenue Ratio|ENOV (Enovis Corporation) - Company Value to Revenue|Integra LifeSciences - Business Value to Revenue|ESTA (Establishment Labs Inc) - EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Beta Bionics, Inc. BBNX|Enterprise Value-to-Revenue Ratio IRADIMED Corp (IRMD)|Embecta Corp. (EMBC) - Enterprise Value-to-Sales Ratio|Tandem Corp - Company Value to Revenue|EV/Sales Multiple SI-BONE, Inc. SIBN|Orthofix Medical - EV/Sales Multiple|Enterprise Value to Sales Volume BVS|OrthoPediatrics (KIDS) - Enterprise Value-to-Revenue Ratio|Enterprise Value to Sales Volume TMCI (Treace Corp)|Enterprise Value-to-Revenue Ratio blade.com|Company Value to Revenue Carlsmed Inc (CARL)|EV/Sales Multiple RXST|CLPT - Enterprise Value-to-Revenue Multiple|Enterprise Value-to-Revenue Ratio Stereotaxis, Inc. STXS|STIM: Company Value to Revenue Ratio|SGHT: Company Value to Revenue|Orchestra BioMed Inc. - Enterprise Value-to-Revenue Coefficient|ANIK: EV/Sales Multiple|NSPR - Total Company Value-to-Revenue Ratio|ZJYL (Jin Medical) - EV/Sales Multiple|Vivani Medical (VANI) - Total Company Value-to-Revenue Ratio|EV/Sales Multiple XTNT|EV/Sales Multiple n1mtc.com (NMTC)|Modular Medical Inc - Company Value to Revenue|Myomo, Inc (MYO) - Enterprise Value-to-Revenue Multiple|COCH: Company Value to Revenue|Total Company Value-to-Revenue Ratio Vivos Therapeutics VVOS|enVVeno Medical Corp. (NVNO) - Enterprise Value-to-Revenue Ratio|Sintx Technologies - Business Value to Revenue|Enterprise Value-to-Revenue Ratio Tenon Medical Inc.|LFWD: Business Value to Revenue|EV/Sales Multiple AMIX|Enterprise Value-to-Revenue Coefficient IVF|Enterprise Value-to-Revenue Ratio Bone Biologics BBLG|Total Company Value-to-Revenue Ratio axonics.com (AXNX)|BIOL - Enterprise Value-to-Revenue Ratio|Dynatronics (DYNT) - Company Value to Revenue|Paragon 28, Inc. (FNA) - Enterprise Value-to-Revenue Ratio|INVO - Total Company Value-to-Revenue Ratio